RU2012113138A - AUTOMATED RADIOCHEMICAL SYNTHESIS - Google Patents
AUTOMATED RADIOCHEMICAL SYNTHESIS Download PDFInfo
- Publication number
- RU2012113138A RU2012113138A RU2012113138/04A RU2012113138A RU2012113138A RU 2012113138 A RU2012113138 A RU 2012113138A RU 2012113138/04 A RU2012113138/04 A RU 2012113138/04A RU 2012113138 A RU2012113138 A RU 2012113138A RU 2012113138 A RU2012113138 A RU 2012113138A
- Authority
- RU
- Russia
- Prior art keywords
- fluoride
- nitro
- formula
- suitable source
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Способ получения соединения Формулы I:где Rпредставляет собой водород и Rпредставляет собойF; иRпредставляет собой Сгетероцикл; или Rпредставляет собой C(=O)-O-R, где Rпредставляет собой водород или прямой или разветвленный Салкил;включающий:(1) получение соединения-предшественника Формулы Ia:где Rпредставляет собой водород, и Rпредставляет собой уходящую группу, выбранную из нитро, три-Салкиламмония или -I-Ar, где Аr представляет собой фенил, замещенный одной или более группами R, где Rвыбран из водорода, нитро, циано, галогена, Cгидроксиалкила, Скарбоксиалкила, Cалкила, Салкоксиалкила, Cгидроксиалкила, Саминоалкила, Cгалогеноалкила, Сарила, Сгетероарила, Салкиларила, Салкенила и Салкинила; иRтакой, как он определен для Rв Формуле I; и(2) взаимодействие указанного соединения-предшественника с подходящим источником [F]фторида.2. Способ по п.1, где Rпредставляет собой триметиламмоний.3. Способ по п.1, где Rпредставляет собой -I-Аr.4. Способ по п. 1, где Rпредставляет собой нитро.5. Способ по п.1, где Rи Rнезависимо представляют собой С(=O)-O-R, где Rпредставляет собой прямой или разветвлений Салкил.6. Способ по п.5, где Rпредставляет собой этил, изопропил или тpeт-бутил.7. Способ по п.1, где указанный подходящий источник [F]фторида выбран из [F]фторида калия и [F]фторида цезия.8. Способ по п.7, где указанный подходящий источник [F]фторида представляет собой [F]фторид калия и для активирования фторид-иона используют Kryptofix™.9. Способ по п.1, дополнительно включающий:(3) удаление избытка [F]фторида; и/или(4) удаление защитных групп; и/или(5) удаление органического растворителя; и/или(6) приготовление полученного соединения вместе с биосовместимым носителем с получени1. A method of obtaining a compound of Formula I: where R is hydrogen and R is F; and R is a C heterocycle; or R5 is C (= O) -OR, where R is hydrogen or straight or branched Calkyl; comprising: (1) preparing a precursor compound of Formula Ia: wherein R is hydrogen and R is a leaving group selected from nitro, tri- Calkylammonium or -I-Ar, where Ar is phenyl substituted with one or more R groups, where R is selected from hydrogen, nitro, cyano, halogen, Chydroxyalkyl, Scarboxyalkyl, Calkyl, Calkoxyalkyl, Chydroxyalkyl, Saminoalkyl, Chaloalkyl, Caryl, Chaloalkyl, Caryl, Chaloalkyl , Salkenila and Salkinila; and R as defined for R in Formula I; and (2) reacting said precursor compound with a suitable source of [F] fluoride. 2. The method of claim 1, wherein R3 is trimethylammonium. The method of claim 1, wherein R is —I — Ar. 4. The method of claim 1, wherein R is nitro. 5. The method of claim 1, wherein R and R are independently C (= O) —O — R, wherein R is straight or branched C alkyl. The method of claim 5, wherein R is ethyl, isopropyl, or tert-butyl. The method of claim 1, wherein said suitable source of [F] fluoride is selected from [F] potassium fluoride and [F] cesium fluoride. The method of claim 7, wherein said suitable source of [F] fluoride is [F] potassium fluoride and Kryptofix ™ is used to activate the fluoride ion. The method of claim 1, further comprising: (3) removing excess [F] fluoride; and / or (4) removing protective groups; and / or (5) removing the organic solvent; and / or (6) preparing the resulting compound together with a biocompatible carrier to obtain
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0917611.6 | 2009-10-08 | ||
GBGB0917611.6A GB0917611D0 (en) | 2009-10-08 | 2009-10-08 | Automated radiosynthesis |
US25089209P | 2009-10-13 | 2009-10-13 | |
US61/250,892 | 2009-10-13 | ||
PCT/EP2010/065077 WO2011042529A1 (en) | 2009-10-08 | 2010-10-08 | Automated radiosynthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012113138A true RU2012113138A (en) | 2013-11-20 |
Family
ID=41402710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012113138/04A RU2012113138A (en) | 2009-10-08 | 2010-10-08 | AUTOMATED RADIOCHEMICAL SYNTHESIS |
Country Status (15)
Country | Link |
---|---|
US (1) | US8946410B2 (en) |
EP (1) | EP2486040B1 (en) |
JP (1) | JP5870031B2 (en) |
KR (1) | KR20120095359A (en) |
CN (1) | CN102548996B (en) |
AU (1) | AU2010305355B2 (en) |
BR (1) | BR112012007701A2 (en) |
CA (1) | CA2774031A1 (en) |
GB (1) | GB0917611D0 (en) |
IL (1) | IL218454A0 (en) |
IN (1) | IN2012DN02214A (en) |
MX (1) | MX2012003994A (en) |
NZ (1) | NZ598659A (en) |
RU (1) | RU2012113138A (en) |
WO (1) | WO2011042529A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201105445D0 (en) * | 2011-03-31 | 2011-05-18 | Ge Healthcare Ltd | Radiolabelled flumazenil derivatives |
KR101441406B1 (en) * | 2011-05-25 | 2014-11-04 | 주식회사 바이오이미징코리아 | Processes for preparing [18F]flumazenil from diaryliodonium salt precursor |
GB201209082D0 (en) * | 2012-05-24 | 2012-07-04 | Ge Healthcare Ltd | Purification method |
CN112979658B (en) * | 2021-02-22 | 2022-05-31 | 南湖实验室 | Preparation method of flumazenil |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA806016B (en) * | 1979-10-04 | 1981-09-30 | Hoffmann La Roche | Imidazodiazepine derivatives |
CA1184175A (en) * | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
GB8927928D0 (en) * | 1989-12-11 | 1990-02-14 | Roussel Lab Ltd | Chemical compounds |
JP3537914B2 (en) * | 1995-05-18 | 2004-06-14 | 株式会社生体機能研究所 | Method for producing [18F] fluoroaromatic compound |
FI101305B (en) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radioiodinated benzodiazepine derivatives useful as radiopharmaceuticals and their use in diagnostics |
GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
WO2007141529A1 (en) * | 2006-06-09 | 2007-12-13 | Ge Healthcare Limited | Fluoridation method |
GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
-
2009
- 2009-10-08 GB GBGB0917611.6A patent/GB0917611D0/en not_active Ceased
-
2010
- 2010-10-08 CA CA2774031A patent/CA2774031A1/en not_active Abandoned
- 2010-10-08 US US13/394,655 patent/US8946410B2/en not_active Expired - Fee Related
- 2010-10-08 MX MX2012003994A patent/MX2012003994A/en not_active Application Discontinuation
- 2010-10-08 RU RU2012113138/04A patent/RU2012113138A/en not_active Application Discontinuation
- 2010-10-08 JP JP2012532611A patent/JP5870031B2/en not_active Expired - Fee Related
- 2010-10-08 KR KR1020127009090A patent/KR20120095359A/en not_active Application Discontinuation
- 2010-10-08 AU AU2010305355A patent/AU2010305355B2/en not_active Ceased
- 2010-10-08 IN IN2214DEN2012 patent/IN2012DN02214A/en unknown
- 2010-10-08 CN CN201080045665.4A patent/CN102548996B/en not_active Expired - Fee Related
- 2010-10-08 BR BR112012007701A patent/BR112012007701A2/en not_active IP Right Cessation
- 2010-10-08 NZ NZ598659A patent/NZ598659A/en not_active IP Right Cessation
- 2010-10-08 WO PCT/EP2010/065077 patent/WO2011042529A1/en active Application Filing
- 2010-10-08 EP EP10762695.4A patent/EP2486040B1/en not_active Not-in-force
-
2012
- 2012-03-04 IL IL218454A patent/IL218454A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2486040B1 (en) | 2017-06-21 |
JP2013507343A (en) | 2013-03-04 |
CN102548996A (en) | 2012-07-04 |
BR112012007701A2 (en) | 2015-09-08 |
KR20120095359A (en) | 2012-08-28 |
AU2010305355B2 (en) | 2015-09-24 |
JP5870031B2 (en) | 2016-02-24 |
GB0917611D0 (en) | 2009-11-25 |
MX2012003994A (en) | 2012-04-30 |
IL218454A0 (en) | 2012-04-30 |
US8946410B2 (en) | 2015-02-03 |
EP2486040A1 (en) | 2012-08-15 |
CA2774031A1 (en) | 2011-04-14 |
US20120190843A1 (en) | 2012-07-26 |
AU2010305355A1 (en) | 2012-04-05 |
NZ598659A (en) | 2014-02-28 |
CN102548996B (en) | 2016-06-01 |
WO2011042529A1 (en) | 2011-04-14 |
IN2012DN02214A (en) | 2015-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015148006A (en) | DEUTERED NUCLEOSIDE MEDICINES APPLICABLE FOR HCV TREATMENT | |
AR068846A1 (en) | COMPOUNDS DERIVED FROM PIRROLO (2,3D) -PIRIMIDINE INHIBITORS OF PKB ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESS AND USE OF THE SAME AS ANTICANCER AGENTS | |
JP2017508789A5 (en) | ||
RU2015149767A (en) | DEUTERED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | |
RU2012113138A (en) | AUTOMATED RADIOCHEMICAL SYNTHESIS | |
JP2013531029A5 (en) | ||
RU2010133903A (en) | METHOD AND INTERMEDIATE COMPOUNDS FOR PRODUCTION OF 5-BIPHENYL-4-IL-2-METHYLPENTANIC ACID DERIVATIVES | |
RU2015103515A (en) | DERIVATIVE COMPOUND OF ETHERAL 2-AMINONICOTIC ACID AND BACTERICIDE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | |
AR076486A1 (en) | 3 KINASA PHOSFOINOSITIDA INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
JP2015500843A5 (en) | ||
AR068057A1 (en) | ESTERES OF 1-PHENYL-2- (3,5-DICLORO) -PIRIDINA, METHOD OF PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT. | |
RU2011107752A (en) | AGENTS RELATING TO PSMA AND THEIR APPLICATION | |
AR083903A1 (en) | DERIVATIVES OF BENZOOXAZOL AND BENZOTIAZOL SULFONAMIDS, USEFUL TO TREAT CARDIAC RHYTHM DISORDERS AND CANCER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND METHOD TO PREPARE THEM | |
AR088564A1 (en) | PROCESS FOR THE PREPARATION OF AGONISTS AND INTERMEDIATE COMPOUNDS OF b3 | |
PE20091401A1 (en) | PROCEDURES FOR PREPARING AROMATIC ETHERS | |
RU2013108348A (en) | CONDENSED HETEROARILS AND THEIR APPLICATION | |
AR076645A1 (en) | RESORCINOL ISOXAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, SYNTHESIS PROCESS, SYNTHESIS INTERMEDIARIES AND USE OF THE SAME IN NEURODEGENERATIVE DISORDERS AND AS ANTITUMORAL AGENTS. | |
EP3388426A3 (en) | Compounds for protection of cells | |
JP2007515465A5 (en) | ||
AR087212A1 (en) | CRTh2 ANTAGONISTS | |
RU2013138372A (en) | ASETIDINE DERIVATIVES USED FOR TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | |
CO6231027A2 (en) | METHODS AND INTERMEDIARIES TO PREPARE LACTOMA LACTOMA COMPOUNDS OF 8 CARBON ATOMS ACTIVE AS RENINE INHIBITORS | |
RU2014133390A (en) | Isoquinoline and naphthyridine derivatives | |
RU2012152600A (en) | CONTINUOUS METHOD OF ALKYLATION OF CYCLIC TREATMENT AMINES | |
JP2013507343A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150422 |